Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial.
Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial.
复制标题
正念干预可降低非活动性溃疡性结肠炎患者发作的频率和严重程度:II 期随机安慰剂对照试验的结果。
DOI:
10.1093/ibd/izac036
复制
发表时间:
2022
影响因子:
4.9
通讯作者:
Keshavarzian,Ali
中科院分区:
文献类型:
--
作者:
Jedel,Sharon;Beck,Todd;Swanson,Garth;Hood,MeganM;Voigt,RobinM;Gorenz,Annika;Jakate,Shriram;Raeisi,Shohreh;Hobfoll,Stevan;Keshavarzian,Ali
BackgroundUlcerative Colitis (UC) is a chronic, inflammatory disease, characterized by symptomatic periods (flare) interspersed with asymptomatic periods (remission). Evidence suggests that psychological stress can trigger flare. Studies have shown that mindfulness interventions (MI) reduce stress, foster more adaptive coping, and improve quality of life, but have been minimally used for UC patients. The objective of this study was to determine whether participation in an MI results in improvements in UC disease course and inflammatory cascades, mindfulness, perceived stress, and other psychological outcomes in inactive UC patients with limited or no exposure to past MI.MethodsParticipants were randomized to an 8-week MI or control group. Biological and psychological assessments were performed at baseline, post 8-week course, and at 6- and 12-months.ResultsForty-three participants enrolled. The MI increased the state of mindfulness and mindfulness skills, decreased perceived stress and stress response in patients with inactive UC. The MI intervention significantly decreased the incidence of flare over 12 months (P< .05). None of the UC patients in the MI flared during 12 months, while 5 of 23 (22%) control group participants flared during the same period.ConclusionsMIs could be considered as adjuvant treatment for a subset of UC patients with high perceived stress and low state of mindfulness.The trial was registered at clinicaltrials.gov as NCT01491997.